Relationship of Cerebrospinal Fluid Markers to11C-PiB and18F-FDDNP Binding
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
UNLABELLED: The purpose of this study was to investigate the potential relationships between cerebrospinal fluid (CSF) measurements of beta-amyloid-1-42 (Abeta(1-42)) and total tau to (11)C-Pittsburgh compound B ((11)C-PiB) and 2-(1-{6-[(2-(18)F-fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene) malononitrile ((18)F-FDDNP) binding as measured using PET. METHODS: A total of 37 subjects were included, consisting of 15 patients with Alzheimer disease (AD), 12 patients with mild cognitive impairment, and 10 healthy controls. All subjects underwent a lumbar puncture and PET using both (11)C-PiB and (18)F-FDDNP. For both PET tracers, parametric images of binding potential were generated. Potential associations of CSF levels of Abeta(1-42) and tau with (11)C-PiB and (18)F-FDDNP binding were assessed using Pearson correlation coefficients and linear regression analyses. RESULTS: For both global (11)C-PiB and (18)F-FDDNP binding, significant correlations with CSF levels of Abeta(1-42) (r = -0.72 and -0.37, respectively) and tau (r = 0.58 and 0.56, respectively) were found across groups (all P < 0.001, except P < 0.05 for correlation between (18)F-FDDNP and Abeta(1-42)). Linear regression analyses showed that, adjusted for regional volume, age, sex, and diagnosis, global (11)C-PiB uptake had an inverse association with Abeta(1-42) CSF levels (standardized beta = -0.50, P < 0.001), whereas there was a positive association between global (18)F-FDDNP binding and tau CSF levels (standardized beta = 0.62, P < 0.01). CONCLUSION: The good agreement between these 2 different types of biomarkers (i.e., CSF and PET) provides converging evidence for their validity. The inverse association between (11)C-PiB and CSF tau Abeta(1-42) confirms that (11)C-PiB measures amyloid load in the brain. The positive association between (18)F-FDDNP and CSF tau suggests that at least part of the specific signal of (18)F-FDDNP in AD patients is due to tangle formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980
Multimodality image registration by maximization of mutual information
Maes, F., Collignon, A., Vandermeulen, D., Marchal, G., & Suetens, P. (1997) · IEEE Transactions on Medical Imaging · doi:10.1109/42.563664 · Cited by 4,547 · cited 1×
“MR images were aligned to corresponding PET images using a mutual information algorithm (21).”
MethodConsensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 1×
“Biochemical changes in CSF (decrease of Ab1-42 and increase of tau) are thought to indirectly reflect the presence of AD pathology (3).”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., et al. (2008) · Brain · doi:10.1093/brain/awn016 · Cited by 933 · cited 1×
“11C-PiB was designed to measure the amount of fibrillar Ab deposits (4,5), which has been confirmed by a postmortem study in AD (6).”
BackgroundFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 2×
“Those earlier studies, however, were performed in groups consisting mainly of healthy controls (8,9), MCI patients (10), or AD patients (12).”
BackgroundMethodGrimmer, T., Riemenschneider, M., Förstl, H., Henriksen, G., Klunk, W. E., Mathis, C. A., Shiga, T., Wester, H.-J., Kurz, A., & Drzezga, A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.027 · Cited by 278 · cited 2×
“Those earlier studies, however, were performed in groups consisting mainly of healthy controls (8,9), MCI patients (10), or AD patients (12).”
BackgroundMethod
Cited by
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationBiomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Brain Imaging in Alzheimer Disease
Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875
“In the setting of MCI, combined data from nine amyloid PET studies show that 161 of 272 MCI patients were amyloid positive (59%) (Fig. 4; Forsberg et al. 2008; Koivunen et al. 2008; Lowe et al. 2009; Okello et al. 2009; Tolboom et al. 2009; Wolk et al. 2009; Devanand et al. 2010; Jagust et al. 2010; Rowe et al. 2010).”
BackgroundJack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531
Amyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455
Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions
Villemagne, V. L., Doré, V., Burnham, S. C., Masters, C. L., & Rowe, C. C. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2018.9 · Cited by 441
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Palmqvist, S., Mattsson, N., Hansson, O., & Initiative, F. T. A. D. N. (2016) · Brain · doi:10.1093/brain/aww015 · Cited by 400
Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid
Landau, S. M., Lu, M., Joshi, A. D., Pontecorvo, M., Mintun, M. A., Trojanowski, J. Q., Shaw, L. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2013) · Annals of Neurology · doi:10.1002/ana.23908 · Cited by 401
Optimizing Patient Care and Research: The Amsterdam Dementia Cohort
van der Flier, W. M., Pijnenburg, Y. A. L., Prins, N., Lemstra, A. W., Bouwman, F. H., Teunissen, C. E., van Berckel, B. N. M., Stam, C. J., Barkhof, F., Visser, P. J., et al. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132306 · Cited by 398
Self-citationAmsterdam Dementia Cohort: Performing Research to Optimize Care
van der Flier, W. M., & Scheltens, P. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170850 · Cited by 390
Self-citationDetailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375
Palmqvist, S., Zetterberg, H., Blennow, K., Vestberg, S., Andreasson, U., Brooks, D. J., Owenius, R., Hägerström, D., Wollmer, P., Minthon, L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1358 · Cited by 368
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
Schindler, S. E., Gray, J. D., Gordon, B. A., Xiong, C., Batrla‐Utermann, R., Quan, M., Wahl, S., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.013 · Cited by 284
Head (2012) · doi:10.1001/archneurol.2011.845 · Cited by 267
Cerebrospinal Fluid Aβ 42/40 Corresponds Better than Aβ 42 to Amyloid PET in Alzheimer’s Disease
Lewczuk, P., Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. L., Eusebi, P., Kornhuber, J., Morris, J. C., & Fagan, A. M. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160722 · Cited by 253
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology
Sattlecker, M., Kiddle, S. J., Newhouse, S., Proitsi, P., Nelson, S., Williams, S., Johnston, C., Killick, R., Simmons, A., Westman, E., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.09.016 · Cited by 223
“Similarly, positron emission tomography imaging of amyloid burden in the brain correlates with clinical diagnosis of AD, Ab neuropathology at autopsy [3,4,6], and CSFAb1-42 levels [7–10] but is equally impractical for use in large groups of frail elderly patients and is restricted to specialist centers.”
Mattsson, N., Insel, P. S., Donohue, M., Landau, S., Jagust, W. J., Shaw, L. M., Trojanowski, J. Q., Zetterberg, H., Blennow, K., & Weiner, M. W. (2015) · Brain · doi:10.1093/brain/awu367 · Cited by 237
Clinical amyloid imaging in Alzheimer's disease
Herholz, K., & Ebmeier, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70123-5 · Cited by 240
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
Seppälä, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., Pyykkö, O. T., Helisalmi, S., Alafuzoff, I., Hiltunen, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bd0 · Cited by 236
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
“Studies have consistently found a relationship between in vivo amyloid load as assessed by Pittsburgh Compound B (PIB)-PET binding and CSF Ab42, with higher 11CPIB binding correlating with lower CSF Ab42 levels (Fagan et al. 2006; Forsberg et al. 2008; Grimmer et al. 2009; Tolboom et al. 2009).”
BackgroundInfluentialAlzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers
for the Alzheimer’s Disease Neuroimaging Initiative, F. T. A. S., Salvadó, G., Molinuevo, J. L., Brugulat-Serrat, A., Falcon, C., Grau-Rivera, O., Suárez-Calvet, M., Pavia, J., Niñerola-Baizán, A., Perissinotti, A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0478-z · Cited by 195
Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease
Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K. V., & Chételat, G. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.03.014 · Cited by 99
“Values in hippocampus were higher for 18F-FDDNP than for 11C-PIB (Shin et al., 2010; Tolboom et al., 2009a).”
BackgroundMethodInfluentialIn vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
Toledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Carandini, T., Arighi, A., Sacchi, L., Fumagalli, G. G., Pietroboni, A. M., Ghezzi, L., Colombi, A., Scarioni, M., Fenoglio, C., De Riz, M. A., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0543-7 · Cited by 36
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside
Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25
Aβ43 levels determine the onset of pathological amyloid deposition
Tambini, M. D., Yin, T., Yesiltepe, M., Breuillaud, L., Zehntner, S. P., d'Abramo, C., Giliberto, L., & D'Adamio, L. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104868 · Cited by 8
Metadata
- Authors
- Tolboom, N., van der Flier, W. M., Yaqub, M., Boellaard, R., Verwey, N. A., Blankenstein, M. A., Windhorst, A. D., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2009-08-18
- Volume
- 50
- Issue
- 9
- Pages
- 1464-1470
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2111642028
- Cited by
- 160
- References
- 8
- FWCI
- 9.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.